Table 1.

Demographic and health-related characteristics of prostate cancer cases and controls, PCPT, 1994 to 2003

ControlsCasesGleason 2–6Gleason 7—10Gleason 8—10P-valuea
(n = 1,751)(n = 1,683)(n = 1,157)(n = 461)(n = 125)
Age, y
X ± SD63.6 ± 5.663.7 ± 5.663.3 ± 5.564.6 ± 5.665.2 ± 5.80.39
 <60 (n, %)470, 26.8443, 26.3335, 29.094, 20.422, 17.60.98
 60–64570, 32.6546, 32.4376, 32.5152, 33.042, 33.6
 65–69423, 24.2413, 24.5276, 23.9116, 25.229, 23.2
 70+288, 16.4281, 16.7170, 14.799, 21.532, 25.6
Race/ethnicity
 White (n, %)1,389, 79.31,561, 92.81,085, 93.8414, 89.8109, 87.2<0.01
 African-American167, 9.578, 4.647, 4.129, 6.310, 8.0
 Asian/Pacific islander32, 1.86, 0.41, 0.15, 1.11, 0.8
 Hispanic138, 7.936, 2.122, 1.913, 2.85, 4
 Other25, 1.42, 0.12, 0.200
Family history of prostate cancer (n, %)1,389, 79.31,561, 92.81,085, 93.8414, 89.8109, 87.20.85
Smoking
 Never (n, %)602, 34.4599, 35.6430, 37.2153, 33.246, 36.80.52
 Current134, 7.7114, 6.879, 6.831, 6.711, 8.8
 Former1,015, 58.0970, 57.6648, 56.0277, 60.168, 54.4
Diabetes (n, %)127, 7.376, 4.542, 3.630, 6.511, 8.8<0.01
Finasteride study arm (n, %)743, 42.4708, 42.1422, 36.5257, 55.780, 64.00.83
Lycopene (μg/dL) X ± SD37.5, 15.638, 15.838.1, 16.037.6, 15.537.8, 16.20.39
BMI (kg/m2)
 X ± SD27.6, 4.027.4, 4.027.2, 4.028, 3.928.2, 4.00.22
 <25 (n, %)444, 25.4471, 28.0346, 29.9107, 23.227, 21.60.22
 25–29925, 52.8856, 50.9590, 51.0232, 50.361, 48.8
 ≥30382, 21.8356, 21.2221, 19.1122, 26.537, 29.6
Clinical stage
 T1a (n, %)229, 13.7173, 15.131, 6.76, 4.8
 T1b118, 7.187, 7.628, 6.17, 5.6
 T1c875, 52.5624, 54.5239, 52.049, 39.2
 T2a236, 14.2152, 13.372, 15.729, 23.2
 T2b87, 5.245, 3.937, 89, 7.2
 T2c68, 4.133, 2.934, 7.414, 11.2
 T324, 1.47, 0.615, 3.311, 8.8
Missing stage30, 1.825, 2.24, 0.9
Diagnosed for-cause772, 45.9445, 38.5291, 63.197, 77.6
  • aP-values are t-tests for means and χ2 tests for categories, contrasting total cases with controls.